Valeant picks up AstraZeneca psoriasis drug after Amgen exit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
September 2, 2015 10:23 AM EDTBMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement to buy Synergetics USA (NASDAQ: SURG). Analyst Alex Arfaei said that although this is a small... More
AstraZeneca (AZN) Enters Brodalumab Licensing Agreement with Valeant (VRX)
September 1, 2015 6:17 AM EDTAstraZeneca (NYSE: AZN) announced that it has entered into a collaboration agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) under which it will grant an exclusive license for Valeant to develop and commercialise brodalumab.
Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialise brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co.,... More
